NCT01127295 2026-04-14
PHACS
Institut Claudius Regaud
Phase 4 Completed
Clinical Trials
181 trialsNCT01553903 2026-04-14
OXYTAM
Institut Claudius Regaud
Phase 4 Completed
NCT01612871 2026-04-14
MIRHO
Institut Claudius Regaud
Phase 4 Completed
NCT00003140 2026-03-27
Letrozole After Tamoxifen in Treating Women With Breast Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT00893061 2026-03-17
MNEMOSYNE
Centre Oscar Lambret
Phase 3 Completed
NCT03747042 2026-03-16
Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT02767661 2026-02-27
MECCA
Sun Yat-sen University
Phase 3 Completed
NCT07225790 2026-02-27
Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases
Brigham and Women's Hospital
Completed
NCT02499146 2026-02-11
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
Pfizer
Phase 1 Completed
NCT02520063 2026-02-06
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
University of Alabama at Birmingham
Phase 1/2 Completed
NCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT04603183 2025-12-12
ABIGAIL
MedSIR
Phase 2 Completed
NCT04735367 2025-12-09
Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole
Pfizer
Completed
NCT03079011 2025-11-18
PADA-1
UNICANCER
Phase 3 Completed
NCT06086340 2025-11-18
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Pfizer
Completed
NCT03671330 2025-10-31
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Novartis
Phase 2 Completed
NCT02297438 2025-10-27
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
Phase 3 Completed
NCT03822468 2025-10-16
AMALEE
Novartis
Phase 2 Completed
NCT06465368 2025-10-01
A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause
Pfizer
Phase 2 Completed
NCT03778931 2025-09-15
EMERALD
Stemline Therapeutics, Inc.
Phase 3 Completed
NCT02958852 2025-09-10
ABC-SE
Lund University Hospital
Phase 2 Completed
NCT04300790 2025-07-29
METALLICA
MedSIR
Phase 2 Completed
NCT05635357 2025-07-28
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole
Brigham and Women's Hospital
Completed
NCT03099174 2025-06-24
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT00601900 2025-05-23
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT03554044 2025-05-21
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT02040857 2025-04-29
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03219476 2025-04-29
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Medical College of Wisconsin
Phase 2 Completed
NCT00265759 2025-04-23
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01958021 2025-03-07
MONALEESA-2
Novartis
Phase 3 Completed
NCT03691493 2025-02-17
ASPIRE
Emory University
Phase 2 Completed
NCT03774472 2025-02-17
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00949598 2025-02-13
Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 3 Completed
NCT02661932 2025-01-31
Brovale
Erasme University Hospital
Phase 4 Completed
NCT04294225 2025-01-28
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
Mayo Clinic
Phase 2 Completed
NCT03644186 2024-12-13
TOUCH
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT06525675 2024-12-13
Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)
MedSIR
Completed
NCT02491983 2024-12-09
PARSIFAL
MedSIR
Phase 2 Completed
NCT01740427 2024-11-14
PALOMA-2
Pfizer
Phase 3 Completed
NCT03962647 2024-10-15
A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase EARLY_PHASE1 Completed
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT03355157 2024-10-01
PADMA
GBG Forschungs GmbH
Phase 4 Completed
NCT06607601 2024-09-23
CARE Initiative: Real-world Emulation of the PALOMA-2 Trial
Aetion, Inc.
Completed
NCT04176354 2024-08-23
Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy
Pfizer
Completed
NCT05163106 2024-08-02
NEOLETRIB
University Hospital, Akershus
Phase 2 Completed
NCT03439046 2024-08-01
BioItaLEE
Novartis
Phase 3 Completed
NCT02188745 2024-07-17
POLLY
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00673335 2024-07-01
LIBER
UNICANCER
Phase 3 Completed
NCT04129216 2024-05-07
The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer
Johns Hopkins University
Phase 2 Completed
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed